SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-031971
Filing Date
2023-11-14
Accepted
2023-11-14 16:12:12
Documents
14
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20231109c_8k.htm   iXBRL 8-K 32662
2 EXHIBIT 99.1 ex_596682.htm EX-99.1 102872
  Complete submission text file 0001437749-23-031971.txt   302520

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvph-20231114.xsd EX-101.SCH 3914
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20231114_def.xml EX-101.DEF 14240
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20231114_lab.xml EX-101.LAB 18823
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20231114_pre.xml EX-101.PRE 14327
8 EXTRACTED XBRL INSTANCE DOCUMENT rvph20231109c_8k_htm.xml XML 4672
Mailing Address 19925 STEVENS CREEK BLVD. SUITE 100 CUPERTINO CA 95014
Business Address 19925 STEVENS CREEK BLVD. SUITE 100 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 231406275
SIC: 2834 Pharmaceutical Preparations